News & Latest Announcements
Metrics That Matter: Measuring Patient Experience in Trials
In business, the adage is simple: what gets measured gets managed. We apply this rigor to our financial performance and operational efficiency, so why not to…
Read article
CAR-T cells vs. Anti-CD20 antibodies: Breaking Through the CNS Barrier in MS
Anti-CD20 monoclonal antibodies like ocrelizumab have advanced MS treatment significantly and offered real hope to many patients. Yet, over time, their limitations have become harder to…
Read article
Co-Created Protocols: Co-Writing the Protocol with Patients
For decades, the clinical trial industry has asked patients for their data, their time, and their bodies. It’s time we started asking for their expertise. True…
Read article
Why CAR-T Cell Therapy is Redefining Autoimmune Treatment
For decades, patients with multiple sclerosis (MS) and other autoimmune diseases have relied on therapies that manage symptoms but rarely alter the long-term trajectory of disease.…
Read article
Why DCT is Not Optional. It’s an Ethical and Business Imperative
When the single biggest reason for patient dropout is the burden of travel, continuing to design every trial around a physical clinic isn’t just inefficient—it represents…
Read article
Why Biotechs Choose Specialized CROs
Biotech companies are increasingly turning to specialized contract research organizations (CROs) to handle their clinical trials, especially for complex and innovative therapies like allogeneic CAR-T. While…
Read article
Kid Gloves vs. Core Change: Is Your Trial Accommodating or Truly Re-engineered?
Many clinical trials today treat patient burden with kid gloves—offering comforts and courtesies to soften the blow of a fundamentally flawed process. But what if we…
Read article
Patient-Centricity in Autoimmune CAR-T
CAR-T therapies have already redefined treatment options in hematologic cancers, and today the same innovation is beginning to transform the way we approach autoimmune diseases such…
Read article
Beyond Friendly: What True Patient Centric Trials Look Like
Nearly 80% of clinical trials fail to enroll on time. Behind this number are delayed treatments and missed opportunities for patients. Too often, the terms friendly…
Read article